All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
On January 19, 2024, the Food and Drug Administration (FDA) authorized a mandate black box warning be included on all chimeric antigen receptor (CAR) T-cell therapies prescribing information, in letters sent to CAR-T therapy manufacturers.
Initially, the benefits of CAR T-cell therapy in lymphoma, leukemia, and multiple myeloma were thought to outweigh the risk of T-cell malignancy. However, in November 2023 the FDA emphasized a need to monitor CAR T-cell therapy clinical trials and post-marketing adverse event reporting throughout patients’ entire lives, enabling the identification of new malignancies and testing for the CAR gene when they occur.
Currently, six CAR T-cell therapies have been approved in the US :
This warning is based on 20 cases of T-cell malignancy reported in 34,000 patients who received approved CAR T-cell therapies. Since then, The International Society for Cell & Gene Therapy published a consensus statement supporting the view CAR T-cell therapies’ benefits to patients outweigh the risks in most cases. However, more information, such as patient characteristics, genetic mutations, and timing of development should be collected to fully elucidate the risk associated with CAR T-cell therapy and T-cell malignancies.
Real-world patient cases: CAR T-cell therapy
At the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session on the ins and outs of CAR T-cells in the real world. Here, Doris Hansen shares a patient case.
My top 5 communications from the 18th IMW
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. He discussed the top five communications from the...
Subscribe to get the best content related to multiple myeloma delivered to your inbox